Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L, page-796

I have looked at a number of ARDS treatments, particularly suppressants of some of the more inflammatory markers. This is why I fundamentally love stem-cells treatments by comparison. They don't block the body's natural processes. They encourage the regenerative ones. Take a look at any successful stem cell treatment (Orthocell [OCC] have been successfully treating tendon injuries by replicating the positive recruitment of tenocyte cells in tendon repair for years).

I was fearful MSB's treatment might be overshadowed by success in some of those suppressants of pro-inflammatory 'angiotensins', but then I saw the MSB results. I've crammed on this thing and its seems to me cytokine storms are at the root of all of this. Importantly not just ARDS related deaths, but also kidney failure, brain and stroke deaths, and heart failure.

The root of the issue is cytokine storms in my opinion (I may be proven wrong) and Remestemcel-L therefore has applications beyond ARDS. I hope the trails are just an early indication of ARDS success and the FDA/MSB also move to non-ARDS trials, whilst using it as a mainstream treatment in ARDS patients in the mean-time.